This future research needs (FRN) report is based on an Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review (CER) titled “First- and Second-Generation Antipsychotics for Children and Young Adults.” The purpose of the CER was to review and synthesize the evidence regarding the benefits and harms of first- and second-generation antipsychotics (FGAs and SGAs) for the treatment of various psychiatric and behavioral conditions in individuals 24 years of age or younger.